Proportional Assist Ventilation vs Pressure Support Ventilation

April 24, 2012 updated by: Robert M. Kacmarek, Massachusetts General Hospital

Proportional Assist Ventilation vs. Pressure Support Ventilation in the Management of Patients Referred to a Respiratory Acute Care Unit

In this study, we want to compare two different kinds of artificial ventilation to see if one encourages faster weaning from breathing support and if one provides better sleep quality. These artificial ventilation types are:

  1. Pressure support ventilation; the standard ventilation that we use for the patients in the Respiratory Acute Care Unit. Pressure support ventilation ventilators use constant air pressure to assist patients with their breathing.
  2. Proportional assist ventilation; a newer way of helping people with their breathing. The air pressure provided by proportional assist ventilation ventilators varies with the size of the breath that a person takes.

Study Overview

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Tracheotomized or endotracheally intubated and mechanically ventilated patients transferred or scheduled to be transferred to the RACU.
  • Age 18 years or older.

Exclusion Criteria:

  • Patients who are weaned from ventilatory support within the first 72 hours of transfer to the RACU. Even though these patients had been randomized, they will be excluded. They will be considered in the intention to treat analysis but the final outcome analysis will be performed after their exclusion.
  • High spinal cord injury
  • Immunosuppressed patients receiving chemotherapy or radiation therapy (< 2 months after chemotherapy or radiation therapy).
  • Neuromuscular/ neurological disease of a progressive nature resulting in chronic ventilator dependence.
  • High risk of mortality within 3 months (severe neurological damage and cancer patients in terminal stages of the disease).
  • Patients unable to trigger the ventilator for any reason.
  • Any patient who is not considered a candidate for weaning from ventilatory support
  • Patients consented for another interventional study.
  • Patients requiring more than 30 days to wean once randomized will be excluded. They will be considered in the intention to treat analysis but the final outcome analysis will be performed after their exclusion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: PAV
Proportional Assist Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
Proportional Assist Ventilation will be used to ventilate the patients.
Other: PS
Pressure Support Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
Pressure Support ventilation will be used to ventilate the patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Length of time mechanically ventilated in the RACU
Time Frame: 30 days
30 days

Secondary Outcome Measures

Outcome Measure
Time Frame
60 day mortality
Time Frame: 60 days
60 days
180 day mortality
Time Frame: 180 days
180 days
Sleep quality
Time Frame: 48 hours
48 hours
Inflammatory mediator levels
Time Frame: 30 days
30 days
Hospital mortality
Time Frame: 30 days
30 days
365 day mortality
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Robert M Kacmarek, PhD, Massachusetts General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2008

Primary Completion (Actual)

May 1, 2010

Study Completion (Actual)

May 1, 2010

Study Registration Dates

First Submitted

November 11, 2008

First Submitted That Met QC Criteria

November 11, 2008

First Posted (Estimate)

November 13, 2008

Study Record Updates

Last Update Posted (Estimate)

April 25, 2012

Last Update Submitted That Met QC Criteria

April 24, 2012

Last Verified

April 1, 2012

More Information

Terms related to this study

Other Study ID Numbers

  • 2008-P-001377

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe